TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients who meet the following criteria at the start of treatment are eligible for the study:~* Receiving stable treatment with anti-hypertensive including ARB for at least 8 weeks at baseline (0W).~* Receiving stable anti-diabetic treatment with/without anti-diabetics for at least 8 weeks at baseline (0W).~* HbA1c\>=6.0%, \<10%~* Seated office SBP 130-159mmHg or DBP 80-99mmHg~* Nocturnal hypertension (SBP\>=115 mmHg) as measured by Home BP during 5days before baseline (0W).~* Age\>=20~Exclusion Criteria:~Patients who meet any of the following criteria are not eligible for the study:~* History of hypersensitivity to empagliflozin~* Breast-feeding, pregnant, possibly pregnant, or plan to become pregnant~* Treated with insulin or SU~* With renal dysfunction (eGFR\<45mL/min/1.73m2)~* With liver dysfunction (AST or ALT is 3 times higher than reference value)~* Hypotension (systolic blood pressure \< 90 mmHg)~* With pituitary gland dysfunction or adrenal gland dysfunction~* Heart failure patients whose NYHA class is IV~* Deemed ineligible for the study due to another reason by investigator~* History of diabetic ketoacidosis or diabetic come within 3 months before enrollment~* History of Acute myocardial infarction, unstable angina, cerebrovascular disease, or transient ischemic attack within 3 months before enrollment~* Patients who have undergone percutaneous transluminal coronary angioplasty (PCI) or coronary artery bypass graftin (CABG) within 3 months before enrollment~* Patients received SGLT2 inhibitor within 8 weeks before enrollment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: EXPERIMENTAL): Empagliflozin 10mg/day is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker \[ARB\]) and diabetes.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker \[ARB\]) and diabetes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of Wilms' tumor~  * Eligible subtypes:~    * Favorable histologies~   * Anaplastic histologies~   * Clear cell sarcoma of the kidney~   * Rhabdoid tumor of the kidney~* Relapsed disease after entry on protocol NWTS-5 (NWTS-Q9401)~PATIENT CHARACTERISTICS:~Age:~* 21 and under at original diagnosis~Performance status:~* Not specified~Life expectancy:~* At least 4 weeks~Hematopoietic:~* Absolute neutrophil count at least 1,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 times normal~* SGOT or SGPT less than 2.5 times normal~Renal:~* Creatinine no greater than 1.5 times normal OR~* Creatinine clearance or GFR at least 70 mL/min~Cardiovascular:~* Shortening fraction at least 27% by echocardiogram OR~* Ejection fraction greater than 50% by echocardiogram or MUGA scan~Other:~* Not pregnant~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* At least 2 weeks since prior chemotherapy and recovered~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No prior therapy for relapsed Wilms' tumor~* Recovered from the toxic effects of any other prior therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- STRATUM A (Type: EXPERIMENTAL): Treatment of children in Stratum A will be determined by the site of relapse and the presence of microscopic or gross residual disease after attempted surgical excision of the relapse.
- Stratum B (Type: EXPERIMENTAL): All children who received combination chemotherapy with Regimen EE - 4A as their initial therapy for Wilms tumor will receive Regimen I and radiation therapy to the site of recurrence. All patients will receive prophylactic trimethoprim /sulfamethoxazole
- STRATUM C (Type: EXPERIMENTAL): All children who received combination chemotherapy with Regimen DD - 4A as their initial therapy for Wilms tumor will be treated with the following chemotherapy. All patients will receive prophylactic trimethoprim/sulfamethoxazole
- STRATUM D (Type: EXPERIMENTAL): Six week cycles of chemotherapy will be given to all patients who do not have progressive disease at the time of each week 0 re-evaluation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Simplifying the Rabies Pre-exposure Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willingness to provide written consent~* Seronegative for rabies~* Belgian soldiers who are deployable and visit the Travel clinic in Brussels during their preparation phase before deployment OR military students at the schools of Belgian Defense are eligible in preparation of an overseas exercise or during the scheduled vaccination program at the end of their studies~* Prepared to follow the study schedule~Exclusion Criteria:~* Subjects who have had rabies vaccination (complete or incomplete) in the past due to post-exposure prophylaxis.~* Subjects with a known allergy to one of the components of the vaccine.~* Immune depressed persons or intake of immunodepressant medication.~* Subjects who take mefloquine~* Planned deployment to overseas areas within 35 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 47 Years
- Healthy Volunteers: t

Study Arms:
- Standard vaccination schedule (Type: ACTIVE_COMPARATOR): One injection will be given on three different days (day 0, day 7 and day 21 or 28)
- Accelerated vaccination schedule (Type: EXPERIMENTAL): Two injections will be given on the same day (day 0 and day 7): one on each forearm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- High-risk biopsy-proven treatment-naïve prostate adenocarcinoma (Gleason score ≥ 8 and/or serum PSA \> 20)~Exclusion Criteria:~* Inability to tolerate or undergo PET/MRI~* Previous or current hematologic or lymphatic disorder (including leukemia, lymphoma, Castleman's disease, etc.)~* Recurrent prostate adenocarcinoma~* Known visceral, osseous, or extrapelvic metastases prior to fluciclovine-PET/MRI~* Known allergy to glucagon or gadolinium-based contrast

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [18F] Fluciclovine PET/MRI (Type: EXPERIMENTAL): \[18F\] Fluciclovine PET/MRI for pretreatment staging of high-risk prostate cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 90 years of age inclusive~* Females can participate if surgically sterile or completed menopause; if able to have children, must have negative serum pregnancy test, agree not to attempt pregnancy and use acceptable contraception while receiving study therapy and for 1 week after~* Onset of symptoms ≥ 48 hours after admission or \<7 days after discharge from an inpatient acute or chronic care facility~* New or worsening infiltrate on chest X-ray obtained within 48 hours prior to randomization~* At least 1 of the following systemic signs:Fever (temperature \>38 C) or hypothermia (rectal/core temperature \<35 C); White blood cell count \>10,000 cells/mm3, or White blood cell count \<4500 cells/mm3, or \>15% band forms.~Exclusion Criteria:~* Pulmonary disease that, in the investigator's judgment, would preclude evaluation of therapeutic response (e.g. lung cancer, active tuberculosis, cystic fibrosis, granulomatous disease, fungal pulmonary infection or recent pulmonary embolism).~* Patients with lung abscess, pleural empyema or post obstructive pneumonia.~* Patients with an estimated creatinine clearance \<16ml/min by Cockcroft Gault formula or patients expected to require haemodialysis or other renal support while on study therapy.~* Acute hepatitis in the prior 6 months, cirrhosis, acute hepatic failure or acute decompensation of chronic hepatic failure.~* Patients receiving hemodialysis or peritoneal dialysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- CAZ-AVI (Type: EXPERIMENTAL): Intra-Venous treatment
- Meropenem (Type: ACTIVE_COMPARATOR): Intra-Venous treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female between 18 and 55 years old~* BCG group: Known to be BCG-vaccinated over 2 years before, PPD positive (range 6-15 mm or any documented value between 6-15 mm on medical file in the past), with no active, chronic or past TB disease as confirmed by chest X ray, negative QuantiFERON-TB Gold In Tube test and negative 6-day lymphocyte tests.~* Infection group: Known to be treated for latent TB, PPDpositive (equal or over 10 mm or documented equal or over 10 mm positive on medical file in the past), previously TB infected but with no active disease confirmed by chest X ray, may have received chemoprophylaxis but with no TB treatment/chemoprophylaxis within the preceding 2 years, positive QuantiFERON-TB Gold In Tube test and/or positive 6-day lymphocyte test.~* Healthy based on medical examination/history at the inclusion~* Signed informed consent~* Prepared to grant authorized persons access to the medical records~* The volunteer is likely to comply with instructions~Exclusion Criteria:~* Granulomatous disease (by chest X-ray)~* Vaccinated with live vaccine 3 months before first vaccination~* Administration of immune modulating drugs (steroids, immunosuppressive drugs or immunoglobulins) 3 months before the first vaccination~* HBV, HCV or HIV sero-positive~* Participation in other clinical trials~* Known hypersensitivity to any of the vaccine components~* Laboratory parameters outside of normal range judged by PI to be clinically relevant~* Pregnant women/planned pregnancy and/or breastfeeding within the trial period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Latent TB infection group (Type: EXPERIMENTAL): The latent TB group will receive two injections of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart.
- BCG vaccinated group (Type: EXPERIMENTAL): The BCG vaccinated group will receive two vaccinations of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Hepatitis C Virus Entry Inhibitor (ITX 5061) in Liver Transplant Recipients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old, ≤ 65 years old~* Plasma HCV RNA positive at time of listing for liver transplantation~* Accepted for liver transplantation for any of:~* End-stage liver disease due to HCV infection~* End-stage liver disease due to HCV infection and alcohol related liver disease (ALD)~* HCC due to HCV~Exclusion Criteria:~* Refusal or inability to give informed consent~* Viral co-infection with either hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Pregnancy or breastfeeding~* Women, of child-bearing potential, who are not willing to practice effective contraception~* Men, sexually active with women of child-bearing potential, who are not willing to practice effective contraception~* Any situation that in the Investigator's opinion may interfere with optimal study participation~* Participation in any clinical study of an investigational agent within 30 days of recruitment~* Transplantation with a donor organ from a HCV positive individual

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Standard liver transplant care (Type: NO_INTERVENTION): Liver Transplantation as per Standard of Care
- ITX 5061 (Type: EXPERIMENTAL): Liver Transplantation as per Standard of Care + ITX5061

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RCT of Brief CBT-I in Primary Care Veterans With Suicidal Thoughts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking~* Veteran seeking or receiving services at the Canandaigua, Buffalo or Syracuse VA Medical Centers~* Demonstrate understanding of informed consent~* Endorse current death/suicidal ideation on item 9 of the Patient Health Questionnaire-9~* An Insomnia Severity Index score \> 10 with trouble sleeping 3 months and at least 1 insomnia-related daytime consequence~* Either:~  * \[a\] a current diagnosis of Major Depressive Disorder, Depression not otherwise specified or PTSD~ * \[b\] a score of \> 16 on the Patient Health Questionnaire for Depression (PHQ-9) or a score \> 46 on the PTSD Symptom Checklist~* If using psychotropic medications the dosage must be stable~Exclusion Criteria:~* History of serious mental illness such as schizophrenia, Bipolar I or II disorder, or current psychiatric conditions such as psychosis, mania, dementia or cognitive impairment~* A suicide attempt within the last 6 months or \[report of SI with active plan or intent in the past month\]~* Currently engaged in inpatient or partial hospitalization programs~* Recent substance dependence disorder with \< 6 months abstinence~* Narcolepsy~* Circadian rhythm disorders~* Restless legs syndrome~* Untreated sleep apnea based upon chart review~* A sleep disorders screening questionnaire and the STOP-BANG sleep apnea questionnaire~  * Sleep medications are not exclusionary, but participants using them must still meet insomnia criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CBT-I (Type: EXPERIMENTAL): Four individual sessions that will last approximately 15-30 minutes each across a 6-week time period, with the option to deliver sessions over the telephone as necessary.
- Sleep Hygiene (Type: ACTIVE_COMPARATOR): Four individual sessions that will last 15-30 minutes each across a 6-week time period, with the option to deliver sessions over the telephone as necessary.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnosis of bipolar I disorder, current episode manic or mixed.~Exclusion Criteria:~* Participants with unstable medical conditions or clinically significant laboratory abnormalities or participants who are rapid cyclers (i.e., have had 4 or more (including current) mood episodes in the past 12 months); have any other psychiatric disorder other than bipolar I disorder as a primary diagnosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Asenapine
- Arm 2 (Type: ACTIVE_COMPARATOR): Olanzapine
- Arm 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OK 2004 Study (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV patients \> 18 years old who provide signed and dated Informed consent.~* HIV patients who have been receiving lopinavir/ritonavir and two nucleosides during at least 4 weeks.~* Plasma HIV RNA \< 50 cop/ml for six months~Exclusion Criteria:~* HIV patients who have stopped a protease inhibitor due to virological failure.~* HIV patients with hepatic or renal insufficiency.~* HIV patients with positive serum HBVAg~* HIV patients who require treatment with a lopinavir/r contraindicated medication.~* HIV pregnant or breastfeeding women.~* Active drug abuse (including alcohol or recreational drugs). Exception, cannabis, provided the investigator is confident in patient adherence. Patients under Methadone program will be accepted too if deemed appropriate by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years or legal age of majority depending on regional law~* Fasting, calculated LDL-C at screening ≥160 mg/dL and following PCSK9i therapy ≥70 mg/dL~* Men and nonpregnant, nonlactating women~Exclusion Criteria:~* Heterozygous (HeFH) or Homozygous (HoFH) Familial Hypercholesterolemia~* Total fasting TG ≥500 mg/dL~* Renal dysfunction or a glomerulonephropathy; eGFR \<30 mL/min/1.73 m2~* Known cardiovascular disease (CVD), peripheral arterial disease (PAD), or cerebrovascular disease (CD)~* History of type 1 or type 2 diabetes~* Uncontrolled hypertension~* Uncontrolled hypothyroidism~* Liver disease or dysfunction~* Gastrointestinal conditions or procedures (including Lap-Band® or gastric bypass)~* History of hematologic or coagulation disorders~* History of malignancy (except non-metastatic basal or squamous cell carcinoma of the skin and cervical carcinoma in situ)~* Unexplained creatine kinase (CK) \>3 × ULN~* Use of a cholesterylester transfer protein (CETP) inhibitor in the last 12 months prior to screening, such as: anacetrapib, dalcetrapib, or evacetrapib~* Pregnant or breast feeding, or planning to become pregnant during treatment and/ or within 30 days after the end of treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bempedoic acid (Type: EXPERIMENTAL): Bempedoic acid 180mg tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
- placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with SCI (\>6months after spinal cord injury) at the T6 level/above~Exclusion Criteria:~* Pregnant and lactating females~* Heart failure, vascular disease, or stroke~* Advanced chronic obstructive pulmonary disease (COPD), liver disease, and chronic kidney disease~* BMI \>38 kg/m2~* Mechanical ventilation dependence~* The following medications are not allowed (potential interaction with buspirone or inhibition of the CYP3A4 system):~  * cimetidine~ * ketoconazole~ * ritonavir~ * itraconazole~ * erythromycin~ * diltiazem~ * verapamil~ * Monoamine oxidase (MAO) inhibitors \[such as Marplan, Nardil, Parmate, Emsam\]~ * Other prohibited concomitant medications include haloperidol, trazodone, or triazolam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Buspirone (Type: ACTIVE_COMPARATOR): This drug will be taken for two week period
- Trazodone (Type: ACTIVE_COMPARATOR): This drug will be taken for two week period
- Placebo (Type: PLACEBO_COMPARATOR): A placebo pill will be taken at bed time for two week period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete